Literature DB >> 9024145

Tissue factor modulates the thrombogenicity of human atherosclerotic plaques.

V Toschi1, R Gallo, M Lettino, J T Fallon, S D Gertz, A Fernández-Ortiz, J H Chesebro, L Badimon, Y Nemerson, V Fuster, J J Badimon.   

Abstract

BACKGROUND: The thrombogenicity of a disrupted atherosclerotic lesion is dependent on the nature and extent of the plaque components exposed to flowing blood together with local rheology and a variety of systemic factors. We previously reported on the different thrombogenicity of the various types of human atherosclerotic lesions when exposed to flowing blood in a well-characterized perfusion system. This study examines the role of tissue factor in the thrombogenicity of different types of atherosclerotic plaques and their components. METHODS AND
RESULTS: Fifty human arterial segments (5 foam cell-rich, 9 collagen-rich, and 10 lipid-rich atherosclerotic lesions and 26 normal, nonatherosclerotic segments) were exposed to heparinized blood at high shear rate conditions in the Badimon perfusion chamber. The thrombogenicity of the arterial specimens was assessed by 111In-labeled platelets. After perfusion, specimens were stained for tissue factor by use of an in situ binding assay for factor VIIa. Tissue factor in specimens was semiquantitatively assessed on a scale of 0 to 3. Platelet deposition on the lipid-rich atheromatous core was significantly higher than on all other substrates (P = .0002). The lipid-rich core also exhibited the most intense tissue factor staining (3 +/- 0.1 arbitrary units) compared with other arterial components. Comparison of all specimens showed a positive correlation between quantitative platelet deposition and tissue factor staining score (r = .35, P < .01).
CONCLUSIONS: Our results show that tissue factor is present in lipid-rich human atherosclerotic plaques and suggest that it is an important determinant of the thrombogenicity of human atherosclerotic lesions after spontaneous or mechanical plaque disruption.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9024145     DOI: 10.1161/01.cir.95.3.594

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  64 in total

Review 1.  Platelet PlA2 polymorphism and thromboembolic events: from inherited risk to pharmacogenetics.

Authors:  P J Goldschmidt-Clermont; C M Roos; G E Cooke
Journal:  J Thromb Thrombolysis       Date:  1999-08       Impact factor: 2.300

2.  Local gene transfer of tissue factor pathway inhibitor regulates intimal hyperplasia in atherosclerotic arteries.

Authors:  P Zoldhelyi; Z Q Chen; H S Shelat; J M McNatt; J T Willerson
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-27       Impact factor: 11.205

Review 3.  Egr-1 is a major vascular pathogenic transcription factor in atherosclerosis and restenosis.

Authors:  Florian Blaschke; Dennis Bruemmer; Ronald E Law
Journal:  Rev Endocr Metab Disord       Date:  2004-08       Impact factor: 6.514

Review 4.  Arterial thrombosis--insidious, unpredictable and deadly.

Authors:  Shaun P Jackson
Journal:  Nat Med       Date:  2011-11-07       Impact factor: 53.440

5.  Blood-born tissue factor in cardiovascular disease: where are we now?

Authors:  Vincenzo Toschi
Journal:  Intern Emerg Med       Date:  2010-09-18       Impact factor: 3.397

6.  Aegyptin displays high-affinity for the von Willebrand factor binding site (RGQOGVMGF) in collagen and inhibits carotid thrombus formation in vivo.

Authors:  Eric Calvo; Fuyuki Tokumasu; Daniella M Mizurini; Peter McPhie; David L Narum; José Marcos C Ribeiro; Robson Q Monteiro; Ivo M B Francischetti
Journal:  FEBS J       Date:  2009-12-15       Impact factor: 5.542

7.  Coronary atherosclerosis and cardiovascular mortality in hemophilia.

Authors:  C J Foley; L Nichols; K Jeong; C G Moore; M V Ragni
Journal:  J Thromb Haemost       Date:  2009-10-26       Impact factor: 5.824

Review 8.  The biology behind the atherothrombotic effects of cigarette smoke.

Authors:  Adam Csordas; David Bernhard
Journal:  Nat Rev Cardiol       Date:  2013-02-05       Impact factor: 32.419

9.  NCX4016 (NO-Aspirin) has multiple inhibitory effects in LPS-stimulated human monocytes.

Authors:  P Minuz; M Degan; S Gaino; A Meneguzzi; V Zuliani; C L Santonastaso; P D Soldato; A Lechi
Journal:  Br J Pharmacol       Date:  2001-10       Impact factor: 8.739

Review 10.  Evolving concepts in the triad of atherosclerosis, inflammation and thrombosis.

Authors:  Roberto Corti; Randolph Hutter; Juan Jose Badimon; Valentin Fuster
Journal:  J Thromb Thrombolysis       Date:  2004-02       Impact factor: 2.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.